Lescol prescribing information |
|
 |
|
We offer 10% discount!
Lescol notes:
Known by the generic name fluvastatin, lescol or lescal is prescribed to lower the overall blood cholesterol along with the blood LDL cholesterol levels. This cholesterol-lowering lescol generic drug can normalize the cholesterol level in the blood by preventing the production of cholesterol by the liver. By lowering LDL cholesterol or so called "bad" cholesterol from the blood, it is possible to reduce the risk for development of coronary artery disease. This in turn helps in lowering the risk for heart attacks. Along with the lowering of bad cholesterol, lescol drug also help in increasing "good" or HDL cholesterol in the blood as a result of which the risk for developing clogged arteries and heart disease is also reduced.
Fluvastatin lescol is also administered for slowing the building up of plaque in the arteries that pave way for coronary heart attacks. Most importantly, lescol xl is prescribed as a last resort for those who fail to lower their cholesterol level with balanced diet, exercise, and weight loss program. According to the lescol prescribing information, you can consume standard Lescol capsule in the form of a single dose per day, mainly at the bedtime. A large dosage of lescol 80 mg capsule is divided in two smaller doses to be taken twice a day. Fluvastatin package insert states that the Lescol XL tablets require to be taken once a day at the bedtime.
The common lescol side effects include: injury, abdominal pain, back pain, diarrhea, constipation, headache, flu-symptoms, indigestion, joint disorders, muscle pain, nausea, nasal inflammation, sore throat, upper respiratory infection etc. Other rare side effects include: chest congestion, allergy, arthritis, dizziness, coughing, dental problems, fatigue, inflamed sinuses, gas, rash, insomnia, urinary tract infection etc. It should be avoided during pregnancy and breast feeding. It also offers drug interactions with medicines like Cholestyramine, Erythromycin, Phenytoin, Rifampin, Niacin etc.
Full prescription information or package insert for Lescol
Click here to read:
Page1 |
Page2 |
Page3 |
Page4
Drug Metab Dispos. 2010 Jun 29. [Epub ahead of print]
Sugatani J, Sadamitsu S, Kurosawa M, Ikushiro SI, Sakaki T, Ikari A, Miwa M.
1 University of Shizuoka;
Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats.
Rats that consumed a high-fat and high-sucrose (HF) diet developed hepatic steatosis. Treatment of HF diet-fed rats with fluvastatin (8 mg/kg) was lethal, followed by an elevation in levels of plasma aspartate aminotransferase and creatine kinase activities and skeletal muscle toxicity. This study was conducted to determine whether nutritional status affects statin-induced adverse effects in rats. Fluvastatin treatment of rats on HF diet led to an increase in systemic exposure, suggesting altered metabolism and elimination. In fact, although hepatic Mrp2 and Mdr1b protein levels were not significantly changed by fluvastatin treatment for 8 days of rats on HF diet, the Oatp1, Mrp3, CYP1A, CYP2C, UGT1A1, and UGT1A5 protein levels were moderately decreased and the Oatp2, CYP3A and UGT2B1 protein levels were markedly suppressed. No significant difference in the baseline level of Oatp1, Oatp2, Mrp2, Mrp3, Mdr1b, CYP1A, CYP2C, CYP3A, UGT1A1, UGT1A5, or UGT2B1 protein was found between the standard diet- and HF diet-fed groups. In addition, the mRNA levels of Oatp2, CYP2C11, and CYP3A1/2 were markedly decreased in HF diet-fed and fluvastatin-treated rats. There was no significant difference in the glucuronidation activities against fluvastatin between 4 groups. In liver cell nuclei, levels of constitutive androstane receptor, pregnane X receptor, and hepatocyte nuclear factor 4alpha proteins were decreased in fluvastatin-treated HF diet-fed rats, which correlated with the decrease in Oatp2, CYP2C, and CYP3A. Taken together, these results indicate that nutritional status may influence adverse effects of fluvastatin by increasing systemic exposure through modulation of hepatic uptake and elimination.
Acta Microbiol Immunol Hung. 2010 Jun;57(2):147-55.
Prochnau D, Rödel J, Prager K, Kuersten D, Heller R, Straube E, Figulla HR.
Friedrich-Schiller-University of Jena Department of Internal Medicine/Cardiology Jena Germany Friedrich Schiller University Department of Internal Medicine I Erlanger Allee 101 07747 Jena Germany.
Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Expert Opin Drug Saf. 2010 Jun 17. [Epub ahead of print]
Voûte MT, Winkel TA, Poldermans D.
Department of Vascular Surgery, Suite Z-838, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.
Curr Vasc Pharmacol. 2010 May 28. [Epub ahead of print]
Rizos EC, Agouridis AP, Elisaf MS.
Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece. egepi@cc.uoi.gr.
The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review.
Curr Drug Metab. 2009 Nov;10(9):1009-47.
Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF.
College of Acupuncture and Massage, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
Hepatogastroenterology. 2009 Nov-Dec;56(96):1704-9.
Mihăilă R, Nedelcu L, Frățilă O, Rezi EC, Domnariu C, Ciucă R, Zaharie AV, Olteanu A, Bera L, Deac M, Mihăilă R.
Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C.
Zhonghua Yu Fang Yi Xue Za Zhi. 2009 Dec;43(12):1064-8.
Zeng YC, Hu MY, Qu SL, Zhou GY.
Nutrition Department, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
[Effects of lycopene on blood lipid and red blood cell of rat with hypercholesterolemia] [Article in Chinese]
Folia Histochem Cytobiol. 2009 Jan;47(3):363-5.
Galus R, Sajjad E, Niderla J, Borowska K, Włodarski K, Włodarski P, Jówiak J.
Department of Histology and Embryology, Center for Biostructure, Medical University of Warsaw, Warsaw, Poland.
Fluvastatin increases tyrosinase synthesis induced by UVB irradiation of B16F10 melanoma cells.
Curr Opin HIV AIDS. 2008 May;3(3):240-6.
Martínez E, Leyes P, Ros E.
Infectious Diseases Unit, IDIBAPS Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Effectiveness of lipid-lowering therapy in HIV patients.
Eur Ann Allergy Clin Immunol. 2008 Nov;40(3):84-9.
Folli C, Descalzi D, Bertolini S, Riccio AM, Scordamaglia F, Gamalero C, Barbieri M, Passalacqua G, Canonica GW.
Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Effect of statins on fibroblasts from human nasal polyps and turbinates.
PPAR Res. 2008;2008:316306. Epub 2008 Dec 24.
Seo M, Inoue I, Ikeda M, Nakano T, Takahashi S, Katayama S, Komoda T.
Department of Biochemistry, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan.
Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells.
Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Mar;36(3):199-204.
Tian CX, Li Y, Wang M, Xia ZE, Li XY, Huang CX.
Department of Clinical Laboratory Science, Renmin Hospital of Wuhan University, Wuhan 430060, China.
[Association between inflammatory cytokine CD40 gene polymorphism and risk of acute coronary syndrome] [Article in Chinese]
Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Sep;36(9):807-11.
Shen J, Zhang RY, Zhang Q.
Department of Cardiology, Shanghai Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China.
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina] [Article in Chinese]
Adv Funct Mater. 2007;17(13):2085-2093.
Benoit DS, Collins SD, Anseth KS.
Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80309.
Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2.
Kardiologiia. 2007;47(11):9-13.
Soboleva GN, Pogorelova OA, Kuznetsova TV, Masenko VP, Fomicheva OA, Chernova NA, Rogoza AN, Balakhonova TV, Karpov IuA.
Cardiology Research Complex, ul Tretiya Cherepkovskaya 15a, Moscow, Russia.
[Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease] [Article in Russian]
Bratisl Lek Listy. 2007;108(9):388-92.
Gajdos M, Krivosikova Z, Uhliar R.
Slovak Medical University, Bratislava, Slovakia. martin.gajdos@szu.sk
A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia.
Clin Ther. 2007 Nov;29(11):2385-94.
Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH.
Department of Epidemiology & Preventive Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Leuk Res. 2006 Sep 20;
Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A.
Myeloma Research Group, Department of Clinical Haematology and Bone Marrow Transplantation, Ground Floor, South Block, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Here the scientists investigated the anti-myeloma potential of zoledronate in comparison to, and in combination with, two other inhibitors of the mevalonate pathway: the HMGCoA reductase inhibitor fluvastatin and the farnesyl transferase inhibitor SCH66336. The study reached the conclusion that the mechanisms of geranylgeranylation inhibition mediated anti-myeloma effects warrant further evaluation and may provide novel targets for future therapeutic development.
Cleve Clin J Med. 2003 Jun;70(6):561-6.
Messerli AW, Aronow HD, Sprecher DL.
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
The given review suggests that all cardiac patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention.
Metabolism. 2004 Jun;53(6):733-9.
Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N.
Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.
Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction.
The present study was to understand whether reduction of sdLDL by pharmacological intervention can improve endothelial function. The given study suggested that an increased sdLDL was linked to endothelial dysfunction in overweight postmenopausal women and fluvastatin treatment improved endothelial dysfunction by decreasing the atherogenic sdLDL fraction in this population.
Am J Cardiol. 2004 Jun 1;93(11):1419-21, A10.
Fujimoto K, Hozumi T, Watanabe H, Shimada K, Takeuchi M, Sakanoue Y, Shimizu N, Ostuka R, Kawase Y, Sakamoto K, Yoshiyama M, Baba Y, Haze K, Yoshikawa J.
Department of Internal Medicine and Cardiology, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia.
The given review suggest that coronary flow reserve increased significantly after lipid-lowering therapy, and coronary microcirculation was improved in patients with hypercholesterolemia.
BJU Int. 2005 Jan;95(1):110-6.
Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C, Homering M, Segerson T, Eardley I; Vardenafil Study Group.
Department of Urology, CHU de Bicetre, AP-HP, 78 rue du General Leclerc, 94272 Le Kremlin Bicetre Cedex, France.
Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age.
The given study was to assess the efficacy and safety of vardenafil in the treatment of erectile dysfunction (ED) in men of different age groups. The study resulted that vardenafil is an effective and generally well-tolerated treatment for ED, irrespective of age.
Lescol review article...
|
|
Antilipemic agents
 Lescol prescribing information
Buy here
|
|
My Basket
